Published • loading... • Updated
Moderna Outlines Next Phase of Growth at Analyst Day
Moderna said intismeran is ready for commercialization after Phase 3 results and lifted its 2026 revenue outlook to 15% to 25%.
Summary by Rutland Herald
4 Articles
4 Articles
Moderna's Analyst Day Leaves Investors Asking for the 2027 Map
Moderna used its analyst day to sketch a brighter commercial picture, but the market wanted a timetable. Shares slipped 2.6% on the day, with media reports pointing to the company’s decision to hold back its formal 2027 revenue guidance until fourth-quarter results are published. That omission sits at the heart of the skepticism. Investors are […]
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
